Related Experiment Video
Updated: Jun 5, 2026
06:48
On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
Published on: May 31, 2020
Label-Free Raman Spectroscopy Reveals Metabolic Signatures Associated with MGMT Promoter Methylation Status in
Dou Lu1,2, Lijun Zhu3, Jing Pan2
1School of Medical Imaging, Xuzhou Medical University, Xuzhou 221004, China.
Analytical Chemistry
|June 3, 2026
Summary
Raman spectroscopy reveals distinct metabolic fingerprints in glioblastoma (GBM) tumors based on O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. This finding offers new avenues for predicting and overcoming temozolomide (TMZ) resistance in GBM patients.
Area of Science:
- Biochemistry
- Oncology
- Spectroscopy
Background:
- Glioblastoma (GBM) treatment response to temozolomide (TMZ) is critically dependent on O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation.
- The unmethylated MGMT subtype, prevalent in GBM, exhibits universal TMZ resistance, necessitating novel therapeutic strategies.
- Current methylation detection methods lack the ability to provide targetable metabolic information, hindering the development of metabolic interventions.
Purpose of the Study:
- To elucidate methylation-associated metabolic signatures in GBM while minimizing biological background noise.
- To establish a validation framework for identifying metabolic differences linked to MGMT methylation status.
- To assess the potential of Raman spectroscopy (RS) for determining MGMT methylation status and guiding therapeutic strategies.
Main Methods:
- Utilized CRISPR-engineered GBM cell models for stepwise validation of metabolic signatures.
- Employed Raman spectroscopy (RS) to analyze metabolic fingerprints in CRISPR-dCas9-edited GBM cell lines.
- Validated RS-identified metabolites using liquid chromatography-mass spectrometry and developed a Raman classification model for clinical specimens.
Main Results:
- MGMT hypermethylated (MGMT-HYPER) GBMs showed elevated saturated fatty acid (SFA) peaks, while MGMT hypomethylated (MGMT-HYPO) GBMs exhibited enhanced peaks for deoxyribonucleic acid (DNA), amino acids, and unsaturated fatty acids (UFAs).
- A Raman classification model achieved a 94.5% area under the curve (AUC) in distinguishing MGMT methylation status across 62 clinical specimens.
- Demonstrated correlations between specific metabolite levels (SFA, DNA, UFA) and MGMT methylation status across different tumor subtypes.
Conclusions:
- Raman spectroscopy holds significant potential for assessing MGMT methylation status in GBM tumors.
- Elucidated distinct metabolic signatures associated with differential MGMT methylation in GBM, offering potential therapeutic targets.
- These findings provide a foundation for developing metabolic interventions to overcome TMZ resistance in GBM.